Iovance Biotherapeutics (IOVA) Non-Current Debt (2012 - 2024)
Iovance Biotherapeutics (IOVA) posted quarterly Non-Current Debt of $1.0 million for Q4 2024, little changed year-over-year from $1.0 million in Q1 2024, and little changed quarter-over-quarter from $1.0 million in Q1 2024.
Iovance Biotherapeutics (IOVA) Non-Current Debt (2012 - 2024) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Non-Current Debt for 5 consecutive years, with $1.0 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Non-Current Debt changed 0.0% year-over-year to $1.0 million; the TTM figure through Dec 2024 stood at $1.0 million (changed 0.0% YoY), while the FY2024 annual figure was $1.0 million, changed 0.0% from the prior year.
- Non-Current Debt held at $1.0 million in Q4 2024 per IOVA's latest filing, from $1.0 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $1.0 million in Q1 2021 and bottomed at $1.0 million in Q1 2021.
- Historically, Non-Current Debt has averaged $1.0 million across 4 years, with a median of $1.0 million in 2021.
- On a YoY basis, Non-Current Debt climbed as much as 0.0% in 2022 and fell as far as 0.0% in 2022.
- Iovance Biotherapeutics' Non-Current Debt stood at $1.0 million in 2021, then changed by 0.0% to $1.0 million in 2022, then changed by 0.0% to $1.0 million in 2023, then changed by 0.0% to $1.0 million in 2024.
- Business Quant data shows IOVA's Non-Current Debt at $1.0 million in Q4 2024, $1.0 million in Q1 2024, and $1.0 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.00 Mn |
| Mar 31, 2024 | 1.00 Mn |
| Dec 31, 2023 | 1.00 Mn |
| Sep 30, 2023 | 1.00 Mn |
| Jun 30, 2023 | 1.00 Mn |
| Mar 31, 2023 | 1.00 Mn |
| Dec 31, 2022 | 1.00 Mn |
| Sep 30, 2022 | 1.00 Mn |
| Jun 30, 2022 | 1.00 Mn |
| Mar 31, 2022 | 1.00 Mn |
| Dec 31, 2021 | 1.00 Mn |
| Sep 30, 2021 | 1.00 Mn |
| Jun 30, 2021 | 1.00 Mn |
| Mar 31, 2021 | 1.00 Mn |
| Sep 30, 2012 | 250,000.00 |